Best of SWOG: Our 10th Webinar

What started in the depths of the Covid-19 pandemic as a way to still connect when remote, to share research results, has grown into a regular – and popular – forum for keeping SWOG members informed about some of the trials they’ve contributed to.

We host these Best of SWOG webinars twice a year. Our early summer event highlights some of the key work SWOG has presented at the ASCO Annual Meeting, while the January webinar features some of the most significant results we’ve published or presented throughout the previous year. We typically get 300 to 400 registrations (sometimes more).

Here are the speakers and topics we’ll feature at our next installment, set for 

Wednesday, January 28th, 2-3 ET/11-12 PT (register here):

• Dr. Joe Unger will discuss details of his study of the special role of federal sponsorship in the design and conduct of cancer treatment trials that feature a drug or biological agent, findings he presented at the ASCO Quality Care Symposium last fall.

• Dr. Terri Parker, study chair of SWOG’s S1702 trial, which treated patients with relapsed and/or refractory AL amyloidosis with isatuximab, will present on the primary results of that trial, which were published in the journal Blood in September.

• Dr. Reshma Jagsi, study chair of SWOG’s S1706 trial, which looked at radiotherapy with or without the PARP inhibitor olaparib for patients with inflammatory breast cancer, presents results of an analysis of treatment-related adverse events among these patients, findings she delivered in an oral presentation at the recent ASTRO annual meeting. 

• Dr. Natasha Kwendakwema will present a secondary analysis of longitudinal changes in the credit status of patients with metastatic colorectal cancer enrolled to our S1417CD financial toxicity study. That study found that, even with health insurance, almost three-fourths of these patients experienced major financial hardship within one year of their diagnosis.

• Dr. Rahul Banerjee will present findings from a secondary analysis of data from patients newly diagnosed with multiple myeloma who were treated in SWOG’s S0777 or S1211 trial. Patients receiving standard induction therapy for the disease frequently struggle with the side effects of dexamethasone, and dex doses are often reduced. Dr. Banerjee examined the association between dexamethasone dose intensity and survival outcomes in these patients.

One of the key benefits of attending our Best of SWOG webinars live is the chance to ask your own questions of the presenter. Each of the five eight-minute presentations is followed by about four minutes for Q & A. All within the duration of a standard lunch hour (but not sure who gets a lunch hour these days).

Email invitations to register for the event have gone out to members, but you can also register here. I’ll be there, and I hope you will be too!